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Summary Objective: This retrospective study documented long-term outcome of pa-
tients receiving vagus nerve stimulation (VNS) therapy for pharmacoresistant epilepsy.
Methods: Medical charts of 28 patients implanted for 5 years or longer were reviewed
for changes in seizure frequency after 1 year of VNS therapy and at follow up, which
ranged from 5 to 7 years. Numbers of antiepileptic drugs (AEDs) taken by the pa-
tients were also computed at 1 year and follow up. One patient had died and one had
discontinued VNS therapy; data were available for 26 patients. Results: The median
percent change in seizure frequency from baseline increased from −28% (P = 0.0053,
Wilcoxon signed-rank test) at 12 months to −72% (P < 0.0001) at follow up. Some pa-
tients whose seizure frequency was not reduced during the initial 12 months of VNS
therapy did experience reductions in seizure frequency during the follow-up period.
Conclusion: In this retrospective study, the effectiveness of VNS therapy increased
over time. Physicians should be aware that response to VNS therapy may be delayed
for some patients.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Clinicians who treat patients with vagus nerve stim-
ulation (VNS) therapy for epilepsy are acquainted
with the technique of adjusting stimulation param-
eters to optimize effectiveness for the individual
patient. Several studies have shown that the effec-
tiveness of VNS therapy increases with time1 and
have suggested a cumulative effect of VNS therapy
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in reducing the frequency of seizures.2—4 Although
some attention has been devoted to tailoring VNS
therapy to achieve maximum effectiveness,5 lit-
tle discussion has focused on the length of time
that clinicians should continue VNS therapy before
determining that it is ineffective for a particular
patient. Schachter6 cautions against premature
cessation of VNS therapy and encourages the clin-
ician to continue the treatment for up to 2 years
before discontinuing it on the basis of inefﬁcacy.
Numerous studies have described the safety and
effectiveness of VNS therapy.6 In addition to re-
ducing the frequency of seizures, other reported
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beneﬁts have included reductions in the severity of
seizures7 as well as improvements in quality of life.6
Reports of improved alertness, memory, and mood
have prompted the manufacturer of the VNS ther-
apy system (Cyberonics, Inc., Houston, TX, USA)
to undertake clinical trials among patients with
intractable depression.8 In this university-based
epilepsy center, we are aware of patients who
continued VNS therapy, even though they had not
experienced any reduction in the frequency of
seizures after 12 months of treatment. We there-
fore undertook a retrospective record review to
identify beneﬁts other than seizure reduction and
evaluate whether these patients attained some
reduction in seizure frequency after the initial 12
months of VNS therapy. At the same time, we inves-
tigated whether patients whose seizure frequency
decreased during the ﬁrst year subsequently expe-
rienced greater reductions.
Methods
We conducted a retrospective review of records of
patients receiving VNS therapy for 5 years or more
at this university-based epilepsy center. Of the 28
records reviewed, 26 provided usable data. One of
the 28 patients had died of SUDEP and a second had
discontinued VNS therapy because beneﬁts did not
outweigh side effects. Several of the patients had
participated in the clinical trials conducted before
FDA approval9 of VNS therapy for commercial use
in 1997, thereby accounting for some follow-up pe-
riods that exceeded 5 years.
The records review collected data regarding the
number of years the patients had received VNS ther-
apy; epilepsy syndromes; types of seizures reported
at baseline and follow up; number of antiepileptic
drugs (AEDs) prescribed at baseline, after 1 year of
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Figure 1 At follow up, the median number of antiepileptic drugs (AEDs) was unchanged from baseline, but the
number of patients taking three or four AEDs decreased and one patient discontinued AED therapy.
VNS therapy, and at follow up; seizure frequency
at baseline; percent reduction of seizure frequency
from baseline at 1 year and follow up; and the per-
centage of seizure frequency reduction between 1
year and follow up.
Maximum increase and decrease in seizure fre-
quency was bounded at −100 and +100%. The sta-
tistical signiﬁcance of changes in seizure frequency
was measured with the Wilcoxon signed-rank test.
Results were considered statistically signiﬁcant
when P ≤ 0.05.
Results
The follow-up period for the 26 patients, 14 males
and 12 females, ranged from 5 to 7 years. Records
were available for 5 years for 17 patients, 6 years
for 3, and for 7 years for 6. Median age at the onset
of seizures was 8 years (range, 0—44), and median
age at implantation was 35 years (range, 18—55).
Epilepsy syndromes were partial (24 patients),
atypical absence (1 patient), and generalized (1
patient). Six of the patients had previously under-
gone unsuccessful epilepsy surgery. Two patients
with left mesial temporal sclerosis had declined
epilepsy surgery. One patient had inoperable left
neocortical temporal epilepsy in which the seizure
focus was co-localized with language; surgery
would have resulted in major language deﬁcits.
Five patients had widespread seizure onset in one
hemisphere and were not considered to be good
candidates for surgery. Five patients had severe
neonatal insult; four had idiopathic epilepsy, which
may have been multifocal, and the remaining three
had severe head injury.
Fig. 1 shows the number of patients taking zero to
four AEDs at each time point. At baseline and 1 year,
the median number of AEDs was two (range, 1—4).
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Figure 2 The median number of seizures per month was
decreased after the initial 12 months of VNS therapy and
was further decreased by follow up.
At follow up, the median number of AEDs remained
at two, but the range had increased from zero to
four.
Reductions in seizure frequency across time are
shown in Fig. 2. Median seizure frequency at base-
line was 16.5 seizures per month (range, 2—2800).
After 1 year of VNS therapy, the median percent
change in seizure frequency was−28% (range,−100
to+100), the median number of seizures per month
was 8.5 (range, 0—1400; P = 0.0053), and seizure
frequency and type remained unchanged for six pa-
tients. At follow up, the median percent change in
seizure frequency was−72% (range,−100 to+100),
and the median number of seizures per month was
5 (range, 0—36.5; P < 0.0001). Between 1 year and
follow up, the median percent change in seizure
frequency was an additional −33% (range, −100—
100; P < 0.0001). During this interval, seizure fre-
quency did not change for 8 of the 26 patients and
decreased for 18 patients; 8 patients had reductions
<50% and 10 patients had reductions ≥50%. By fol-
low up, seizure frequency had decreased for four of
the six patients whose seizure frequency and type
had not changed during the initial 12 months of VNS
therapy.
Discussion
In this retrospective review, the median percent
reductions in seizure frequency were statistically
signiﬁcant not only during the ﬁrst year of VNS
therapy, but also between 1 year and follow up,
which ranged from 5 to 7 years. The patients with
the longest follow up were selected for the VNS
therapy clinical trials because all other treatment
modalities had been exhausted. Given the estab-
lished intractability of this group, the favorable
outcome and long-term retention (only one patient
discontinued) is remarkable.
Of the six patients whose seizure frequency
and type had not changed after 12 months of VNS
therapy, four experienced reductions in seizure
frequency by follow up. These six patients were
continued on VNS therapy beyond the initial 12
months because they experienced other bene-
ﬁts, including shorter seizures, reduced postictal
confusion, and interrupted seizures or diminished
seizure severity, with magnet activation of VNS
therapy. Interestingly, ﬁve of these six patients
had undergone unsuccessful epilepsy surgery be-
fore they were implanted with the VNS therapy
device.
An early investigation of VNS therapy sug-
gested that patient response during the ﬁrst 3
months of treatment could foretell subsequent
effectiveness,10 but the analysis lacked the lengthy
follow-up period of this study. This study has some
limitations: data were gathered retrospectively
and the number of patients was small. However,
the additional reductions in seizure frequency of
the patients in this study support the premise that
the effectiveness of VNS therapy can increase after
the initial 12 months.
Conclusion
In this retrospective study, the effectiveness of
VNS therapy increased over time. Some patients
have a delayed response and eventually beneﬁt
from VNS therapy. A clinician evaluating a patient
whose seizure frequency has not decreased should
not rush the decision to discontinue VNS therapy.
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